The authors reported the success of IL-17 neutralization to prevent short-term memory impairment and hippocampal glutamatergic dysfunction in early AD stages while prolonged anti-IL-17 infusion delayed cognitive impairment, and reduced peripheral inflammation in later AD stages. Here, IL17A is linked to Cognitive impairment.